Terms: = Ovarian cancer AND CEACAM5, CEA AND Clinical Outcome
5 results:
1. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial.
Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
[TBL] [Abstract] [Full Text] [Related]
2. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.
Togami S; Sasajima Y; Kasamatsu T; Oda-Otomo R; Okada S; Ishikawa M; Ikeda S; Kato T; Tsuda H
Pathol Oncol Res; 2015 Apr; 21(2):487-94. PubMed ID: 25370301
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
[TBL] [Abstract] [Full Text] [Related]
4. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract] [Full Text] [Related]
5. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract] [Full Text] [Related]
